论文部分内容阅读
Background Almost all patients can achieve complete remission (CR) since the introduction of tyrosine kinase inhibitors(TKI) in the combination chemotherapy regimens for newly diagnosedPhiladelphia chromosome-positive acute lymphoblastic leukemia(Ph +ALL).But long-term outcomes remain unsatisfactory without allogeneic hemotopoietic stem cell transplantation (HSCT) at least in adult.Although haploidentical HSCT has become a common treatment in adult patients who lack a HLA matched donor, data on the efficacy of haploidentical HSCT for Ph+ ALL are limited.